Literature DB >> 10803472

The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.

J Bellone1, S Bellone, G Aimaretti, M R Valetto, C Baffoni, G Corneli, C Origlia, E Arvat, E Ghigo.   

Abstract

Aim of the present study was to further clarify the negative GH auto-feedback mechanisms in childhood. To this goal we studied the effects of rhGH and/or GHRH administration on the GH response to GHRH or hexarelin (HEX), a peptidyl GH secretagogue, in normal short children. In 34 prepubertal children (12 girls and 22 boys, age 8.2- 14.2 yr) with normal short stature (normal height velocity and IGF-I levels) the following tests were performed: group A (no.=11): GHRH (GHRH 1 - 29, Geref, Serono; 1 microg/kg iv at 150 min) preceded by saline or GHRH at 0 min; group B (no.=6): GHRH preceded by saline or rhGH (0.005 IU/kg iv at 0 min); group C (no.=6): GHRH preceded by rhGH alone or combined with GHRH; group D (no.=6): HEX (2 microg/kg iv at 150 min) alone or preceded by rhGH. In group A, the GH response to GHRH was not modified by pre-treatment with GHRH (GH peak, mean+/-SEM: 16.7+/-2.9 vs 15.1+/-2.3 microg/l, respectively). In group B, the GH response to GHRH was clearly inhibited by rhGH (8.7+/-2.3 vs 38.8+/-4.5 microg/l, p<0.001); the GH rise after rhGH in group B overlapped with that after GHRH in group A. In group C, the GH response to GHRH after pre-treatment with rhGH (13.2+/-4.0 microg/l) was similar to that in group B and was not significantly modified by pre-treatment with rhGH+ GHRH (6.9+/-2.7 microg/l); the GH rise after rhGH+GHRH was higher (p<0.05) than that after rhGH alone. In group D, the GH response to HEX was significantly blunted by pre-treatment with rhGH (34.1+/-11.7 vs 51.2+/-17.9 microg/l, p<0.05). Our results demonstrate that in childhood the somatotroph response to GHRH is preserved after GHRH while it is inhibited after rhGH administration, which is also able to blunt the GH response to HEX. Thus, the somatostatin-mediated negative GH auto-feedback is already operative in childhood; the reason why the GHRH- induced GH rise is not inhibited by GHRH pre-treatment is unexplained.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803472     DOI: 10.1007/BF03343699

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

1.  Beta-adrenergic modulation of growth hormone (GH) autofeedback on sleep-associated and pharmacologically induced GH secretion.

Authors:  M Kelijman; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1989-12       Impact factor: 5.958

Review 2.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

3.  Repeated GH-releasing hormone administration unravels different GH secretory patterns in normal adults and children.

Authors:  E Ghigo; S Goffi; E Mazza; E Arvat; M Procopio; J Bellone; E E Müller; F Camanni
Journal:  Acta Endocrinol (Copenh)       Date:  1989-05

4.  Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood.

Authors:  J Bellone; G Aimaretti; M R Valetto; S Bellone; C Baffoni; E Arvat; S Seminara; F Camanni; E Ghigo
Journal:  Eur J Endocrinol       Date:  1996-10       Impact factor: 6.664

Review 5.  Human growth hormone and human aging.

Authors:  E Corpas; S M Harman; M R Blackman
Journal:  Endocr Rev       Date:  1993-02       Impact factor: 19.871

6.  Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.

Authors:  E Arvat; L Gianotti; J Ramunni; L DiVito; R Deghenghi; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

7.  Influence of galanin and serotonin on the endocrine response to Hexarelin, a synthetic peptidyl GH-secretagogue, in normal women.

Authors:  E Arvat; B Maccagno; J Ramunni; F Broglio; F Lanfranco; R Giordano; A Benso; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

8.  Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.

Authors:  M Maccario; E Arvat; M Procopio; L Gianotti; S Grottoli; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

9.  Time-dependent reduction and potentiation of growth hormone (GH) responsiveness to GH-releasing factor induced by exogenous GH: role for somatostatin.

Authors:  R Lanzi; G S Tannenbaum
Journal:  Endocrinology       Date:  1992-04       Impact factor: 4.736

10.  Short-term met-hGH infusion inhibits somatotroph response to growth hormone releasing hormone (1-44).

Authors:  M Rosenbaum; S Loche; S Balzano; J M Gertner
Journal:  Metabolism       Date:  1988-02       Impact factor: 8.694

View more
  1 in total

1.  Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

Authors:  M Castagno; A Monzani; S Zanetta; G Genoni; E Giglione; R Ricotti; G Bona; F Prodam; S Bellone
Journal:  J Endocrinol Invest       Date:  2018-02-08       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.